NASDAQ : NTRB

Nutriband Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 6.64 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 80.71M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Details

NameNutriband Inc.
SectorHealthcare
IndustryBiotechnology
Employees13
Founded2016
CeoGareth Sheridan
CountryUnited States
ExchangeNASDAQ
Fiscal YearFebruary - January
Reporting CurrencyUSD
IsinUS67092M2089
Cusip67092M208
Cik1676047
Sic3842
Stock TypeCommon Stock

Key executives

NameTitle
Gareth SheridanFounder, Chief Executive Officer and Director
Serguei MelnikFounder, President, Company Secretary and Executive Chairman
Gerald GoodmanChief Financial Officer and Chief Accounting Officer
Dr. Alan Smith Ph.D.Chief Operating Officer and President of 4P Therapeutics
Dr. Jeffrey Patrick Pharm.D.Chief Scientific Officer
Michael MyerPresident of Pocono Pharmaceutical
Tyler OverkHead of Active Intelligence

Contact

Address121 South Orange Avenue, Suite 1500, Orlando, Florida 32801, United States
Phone407 377 6695
Websitehttps://www.nutriband.com